课题基金 / 基金详情

IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE

IMPAIRED HEPATIC FUNCTION ON PKS OF PIOGLITAZONE
吡格列酮 PKS 导致肝功能受损
批准号:
6120086
负责人:
STEVEN SCHENKER
金额:
$1.64万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
吡格列酮是一种用于治疗非胰岛素依赖型糖尿病的药物,通过激活胰岛素受体的后受体阶段来改善高血糖。口服后,吡格列酮集中在肝脏代谢;本研究旨在评估肝功能受损对吡格列酮在尿和血清中的药代动力学的影响。该研究将评估吡格列酮在已知肝功能损害患者体内的药代动力学变化。
英文摘要
Pioglitazone, a drug being developed for the treatment of non-insulin dependent diabetes, improves hyperglycemia by activating the post-receptor phase of the insulin receptor. After oral administration, pioglitazone is concentrated in the liver where it is metabolized; this study is designed to evaluate the effect impaired hepatic function has on the pharmacokinetics of pioglitazone in urine and serum. The study will evaluate changes in the pharmacokinetics of pioglitazone in subjects with known hepatic impairment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金